Neuronal preconditioning with the antianginal drug, Bepridil

It has recently been shown that the antianginal drug bepridil (BEP) activates mitochondrial ATP-sensitive potassium (mitoKATP) channels and thus confers cardioprotection. Our aim was to investigate whether BEP could induce preconditioning in cultured rat cortical neurons. Although BEP depolarized isolated and in situ mitochondria and increased reactive oxygen species generation, no acute protection was observed. However, a 3-day BEP-treatment elicited dose-dependent delayed neuroprotection against 180 min of oxygen–glucose deprivation (cell viability: untreated, 52.5 ± 0.85%; BEP 1 μmol/L, 59.6 ± 1.53%*; BEP 2.5 μmol/L, 71.9 ± 1.23%*; BEP 5 μmol/L, 95.3 ± 0.89%*; mean ± SEM; *p < 0.05 vs. untreated) and 60 min of glutamate excitotoxicity (200 μmol/L; cell viability: untreated, 54.1 ± 0.69%; BEP 1 μmol/L, 61.2 ± 1.19%*; BEP 2.5 μmol/L, 78.1 ± 1.67%*; BEP 5 μmol/L, 91.2 ± 1.20%*; mean ± SEM; *p < 0.05 vs. untreated), and inhibited the reactive oxygen species surge upon glutamate exposure. The protection was antagonized with co-application of the superoxide dismutase mimetic M40401, but not with reduced glutathione, catalase, or with the mitoKATP blocker 5-hydroxydecanoate. Furthermore, BEP treatment resulted in increased levels of phosphorylated protein kinase C, manganese-dependent superoxide dismutase, glutathione peroxidase, and Bcl-2. Our results indicate that BEP induces delayed neuronal preconditioning which is dependent on superoxide generation but perhaps not on direct mitoKATP activation.